Details of the Drug

General Information of Drug (ID: DMYGJQO)

Drug Name
Ponatinib
Synonyms Iclusig (TN)
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Chronic myelogenous leukaemia 2A20.0 Approved [2]
Thyroid tumor N.A. Approved [2]
ATC Code
L01EA05: Ponatinib
L01EA: BCR-ABL tyrosine kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 532.6
Logarithm of the Partition Coefficient (xlogp) 4.1
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 24 hours (in cancer patients with 45 mg ponatinib once daily) [3]
Metabolism
The drug is metabolized via the esterases and/or amidases []
Vd
The volume of distribution (Vd) of drug is 1223 L []
Chemical Identifiers
Formula
C29H27F3N6O
IUPAC Name
3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
Canonical SMILES
CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
InChI
InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
InChIKey
PHXJVRSECIGDHY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
24826799
ChEBI ID
CHEBI:78543
CAS Number
943319-70-8
TTD ID
D0H0EQ
VARIDT ID
DR00204
INTEDE ID
DR1315
ACDINA ID
D00541
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Modulator [4]
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Modulator [4]
Tyrosine-protein kinase ABL1 (ABL) TT3PJMV ABL1_HUMAN Modulator [4]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Modulator [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [5]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute lymphoblastic leukaemia
ICD Disease Classification 2A85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase Kit (KIT) DTT KIT 2.06E-01 -0.1 -0.14
Fms-like tyrosine kinase 3 (FLT-3) DTT FLT3 2.11E-01 -0.05 -0.16
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 9.45E-01 -5.34E-02 -9.01E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1 -0.1656 1.9043 -1.8013 4.1916
HuO9 GDSC1 -4.1751 2.2437 -5.6674 44.147
NY GDSC1 -2.4448 -0.2533 -2.8181 21.02
NOS-1 [Human HNSCC] GDSC1 -2.4088 2.3232 -3.9266 27.91
G-292 clone A141B1 GDSC1 -2.3771 3.5604 -4.4909 30.5453
CHSA0108 GDSC1 -2.0059 2.2542 -3.5077 23.5016
CHSA8926 GDSC1 -1.5008 3.9525 -3.8839 23.5317
H-EMC-SS GDSC1 -1.4696 2.8151 -3.2909 19.7315
HOS GDSC1 -1.2617 0.5985 -2.0064 9.3443
U2OS GDSC1 -1.1446 0.7678 -1.9857 8.7145
EW-16 GDSC1 -1.0622 0.5118 -1.7863 6.829
ES6 GDSC1 -0.9 2.5935 -2.6909 13.2449
SK-ES-1 GDSC1 -0.7052 2.6952 -2.5839 11.756
A-673 GDSC1 -0.685 0.7603 -1.6075 4.1308
EW-1 GDSC1 -0.5155 1.8126 -1.9999 6.6582
MHH-ES-1 GDSC1 -0.2825 1.4293 -1.653 3.3869
ES7 GDSC1 -0.1682 5.1741 -3.399 15.6841
CHSA0011 GDSC1 -0.135 2.4269 -2.0296 5.8081
SJSA-1 GDSC1 0.163 3.6974 -2.4369 8.0262
MG-63 GDSC1 0.2306 5.9676 -3.493 15.0448
HuO-3N1 GDSC1 0.2653 3.4152 -2.2349 6.3013
ES1 GDSC1 0.3369 2.3151 -1.69 2.3776
SK-PN-DW GDSC1 0.3386 4.3966 -2.6532 9.1106
EW-13 GDSC1 0.4154 9.6836 -5.1878 23.203
CAL-72 GDSC1 0.4812 2.2625 -1.5931 1.5723
EW-7 GDSC1 0.5657 5.1311 -2.8518 9.8936
ES4 GDSC1 0.9125 3.1541 -1.7508 1.8769
EW-24 GDSC1 0.937 2.392 -1.4432 0.4549
EW-18 GDSC1 0.9404 2.8834 -1.6285 1.2113
EW-3 GDSC1 1.0044 3.1457 -1.7037 1.5145
CAL-78 GDSC1 1.2193 7.7566 -3.6678 13.3813
SaOS-2 GDSC1 1.3487 2.9761 -1.4953 0.3981
ES5 GDSC1 1.4383 6.7611 -3.0569 9.138
TC-71 GDSC1 1.7619 3.245 -1.4396 0.147
ES8 GDSC1 1.7663 3.4614 -1.5116 0.2755
EW-11 GDSC1 1.9058 8.3371 -3.4976 10.7684
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 149 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JM1 GDSC1 -0.2532 1.6777 -1.7513 4.0396
EM-2 GDSC1 -11.4396 4.3179 -14.1744 70.7104
EoL-1 GDSC1 -10.7287 -9.1051 -10.7287 99.1869
LAMA-84 GDSC1 -10.6624 -5.9247 -10.71 90.1862
MY-M12 GDSC1 -10.5534 0.1797 -11.7629 74.8221
SUP-B15 GDSC1 -10.4651 2.2721 -12.3676 71.4022
ALL-SIL GDSC1 -10.376 -7.2611 -10.3797 94.447
MEG-01 GDSC1 -10.0759 -7.6048 -10.0766 95.5514
JURL-MK1 GDSC1 -10.0481 -7.8289 -10.0484 96.2835
KCL-22 GDSC1 -9.412 -5.0027 -9.4708 85.6169
Kasumi-1 GDSC1 -7.9975 -5.0861 -8.0106 81.4678
MOLM-13 GDSC1 -7.8538 -4.4742 -7.8883 78.7108
CTV-1 GDSC1 -7.85 -6.387 -7.85 84.6247
MV4-11 GDSC1 -7.7083 -5.5403 -7.7104 81.2538
GA-10 GDSC1 -7.2928 -4.9504 -7.2984 76.6025
SU-DHL-10 GDSC1 -7.2415 18.9104 -16.5195 54.7215
NKM-1 GDSC1 -7.1886 -4.6221 -7.1999 74.9715
Mono-Mac-6 GDSC1 -6.9746 -0.8868 -7.5451 65.1086
SU-DHL-6 GDSC1 -5.8305 -3.9453 -5.8364 60.572
Karpas-231 GDSC1 -5.8221 0.2535 -6.6425 56.5929
GDM-1 GDSC1 -5.624 -2.3333 -5.752 57.1352
SU-DHL-16 GDSC1 -5.3586 -3.4021 -5.3714 54.7983
NU-DUL-1 GDSC1 -5.1445 -3.1857 -5.1607 52.1833
Daudi GDSC1 -4.9883 -0.3429 -5.5403 50.2076
Ku812 GDSC1 -4.9246 2.2122 -6.4333 49.718
DoHH2 GDSC1 -4.7507 -2.876 -4.7707 47.3615
KG-1 GDSC1 -4.7464 -2.1968 -4.8324 47.4276
P32/ISH GDSC1 -4.2994 0.5035 -5.0892 43.9952
EB2 GDSC1 -4.1708 1.896 -5.5139 43.869
SU-DHL-5 GDSC1 -3.6752 -1.7811 -3.7466 34.3002
SU-DHL-4 GDSC1 -3.4546 -2.1962 -3.4693 31.2024
MLMA GDSC1 -3.3438 1.9166 -4.6708 36.4235
SUP-T1 GDSC1 -3.1786 1.4886 -4.3128 33.9975
BV-173 GDSC1 -3.1228 50.367 -28.4511 48.1125
Farage GDSC1 -2.9393 0.0147 -3.4488 27.9644
SIG-M5 GDSC1 -2.8386 -1.5522 -2.8846 23.7029
P30/OHK GDSC1 -2.682 0.2281 -3.2602 25.3145
ALL-PO GDSC1 -2.6358 2.3174 -4.1453 30.2097
YT GDSC1 -2.5563 -1.2255 -2.6382 20.4103
697 GDSC1 -2.458 0.6346 -3.1989 23.7136
CA46 GDSC1 -2.4153 5.6893 -5.567 34.6902
PF-382 GDSC1 -2.3377 2.3113 -3.8522 27.1445
OCI-Ly19 GDSC1 -2.1696 2.0918 -3.5855 24.7591
VAL GDSC1 -2.0476 6.2935 -5.5322 33.0235
NALM-6 GDSC1 -2.0356 -0.3405 -2.3483 15.5228
WIL2 NS GDSC1 -1.9313 1.0658 -2.8669 18.802
NB4 GDSC1 -1.8861 -0.6924 -2.0562 12.6497
MOLT-16 GDSC1 -1.76 -0.6364 -1.9405 11.1549
OCI-AML-5 GDSC1 -1.6654 2.8866 -3.5021 21.9371
QIMR-WIL GDSC1 -1.6013 1.9234 -2.9691 18.0596
CTB-1 GDSC1 -1.5696 7.7739 -5.8485 32.1505
OPM-2 GDSC1 -1.3981 1.1307 -2.393 12.9059
KE-37 GDSC1 -1.3612 0.2496 -1.9279 9.152
K-562 GDSC1 -1.2331 -0.5268 -1.4344 4.7931
OCI-AML-2 GDSC1 -1.2224 -0.6469 -1.3691 4.2508
PL-21 GDSC1 -1.2169 0.5084 -1.9214 8.4977
A4/Fukuda GDSC1 -1.1741 0.8689 -2.062 9.4276
EHEB GDSC1 -1.121 5.4139 -4.2859 24.1835
RPMI-6666 GDSC1 -1.0621 6.1549 -4.6067 25.5218
Karpas-45 GDSC1 -1.0408 6.3746 -4.6986 25.863
VL51 GDSC1 -0.9846 1.754 -2.3414 10.8911
A3/Kawakami GDSC1 -0.9017 1.2375 -2.0145 8.0382
HEL GDSC1 -0.8929 0.1832 -1.4808 3.8053
HC-1 GDSC1 -0.8271 1.5623 -2.1162 8.5752
KMOE-2 GDSC1 -0.822 1.283 -1.9727 7.4327
Jiyoye GDSC1 -0.8143 4.9934 -3.8201 20.4894
TUR GDSC1 -0.7898 0.7927 -1.703 5.2075
BL-41 GDSC1 -0.772 4.6138 -3.5957 18.9864
NK-92MI GDSC1 -0.7499 4.0466 -3.2944 16.9723
SU-DHL-1 GDSC1 -0.7413 6.2822 -4.4045 23.3793
WSU-NHL GDSC1 -0.695 1.8905 -2.175 8.5873
U-698-M GDSC1 -0.69 1.6172 -2.0353 7.4825
JSC-1 GDSC1 -0.6846 1.4005 -1.9235 6.5924
MOLP-8 GDSC1 -0.6824 1.2182 -1.8316 5.8674
HL-60 GDSC1 -0.6808 1.3257 -1.8836 6.2685
Hs 445 GDSC1 -0.6194 4.1087 -3.2204 16.0159
HAL-01 GDSC1 -0.6119 3.0707 -2.6972 12.2837
NOMO-1 GDSC1 -0.6092 1.5426 -1.9366 6.4557
DEL GDSC1 -0.5898 1.6444 -1.9724 6.6734
DND-41 GDSC1 -0.5861 5.4471 -3.8615 19.9141
KOPN-8 GDSC1 -0.5312 3.0795 -2.6387 11.5804
SR GDSC1 -0.5012 1.8177 -1.9919 6.553
Loucy GDSC1 -0.4772 1.8852 -2.0074 6.6007
L-540 GDSC1 -0.4722 2.5854 -2.3486 9.2051
Karpas-620 GDSC1 -0.4508 1.7379 -1.9162 5.8212
ME1 GDSC1 -0.4118 3.0277 -2.5217 10.3229
ML-2 GDSC1 -0.3875 2.3703 -2.1799 7.6567
HDLM-2 GDSC1 -0.3088 3.778 -2.8149 12.1499
U266B1 GDSC1 -0.2661 1.851 -1.8424 4.7506
L-428 GDSC1 -0.2513 2.7951 -2.2891 8.0841
TK [Human B-cell lymphoma] GDSC1 -0.2238 2.0629 -1.9153 5.1866
OCI-AML-3 GDSC1 -0.2228 1.4697 -1.6341 3.1093
MN-60 GDSC1 -0.1405 3.5876 -2.5967 10.0477
BE-13 GDSC1 -0.0661 28.6292 -15.0204 40.7985
BC-3 GDSC1 -0.0621 1.594 -1.5941 2.4826
ARH-77 GDSC1 -0.0599 4.7149 -3.0911 13.3053
Namalwa GDSC1 0.0768 3.1182 -2.2179 6.6507
KMS-12-BM GDSC1 0.1455 1.8599 -1.5953 2.1034
GR-ST GDSC1 0.231 4.604 -2.8273 10.6282
Sc-1 GDSC1 0.2423 6.9085 -3.9471 17.7026
MHH-PREB-1 GDSC1 0.2488 6.1551 -3.5717 15.4761
JJN-3 GDSC1 0.264 2.2176 -1.6871 2.4868
Ramos.2G6.4C10 GDSC1 0.3297 5.3532 -3.1215 12.3582
CESS GDSC1 0.3602 2.8487 -1.9141 3.8202
Granta-519 GDSC1 0.3628 2.3978 -1.712 2.4732
SU-DHL-8 GDSC1 0.4677 10.4857 -5.5452 24.4671
P12-Ichikawa GDSC1 0.4743 2.8805 -1.8628 3.2531
Reh GDSC1 0.5015 6.1742 -3.3992 13.6701
KM-H2 GDSC1 0.5408 5.6118 -3.0994 11.6249
P31/FUJ GDSC1 0.6034 1.6017 -1.2878 0.1768
IM-9 GDSC1 0.6091 1.7653 -1.3436 0.3219
DB GDSC1 0.6503 2.9302 -1.7889 2.4784
ST486 GDSC1 0.6807 10.3098 -5.2972 22.8912
MOLT-4 GDSC1 0.7114 7.0197 -3.6619 14.6902
CCRF-CEM GDSC1 0.7435 5.2922 -2.8107 9.1629
SCC-3 GDSC1 0.7482 1.9459 -1.3552 0.2874
SUP-HD1 GDSC1 0.7654 5.4683 -2.8797 9.5735
SUP-M2 GDSC1 0.7735 2.062 -1.3872 0.3682
AMO1 GDSC1 0.7802 2.8383 -1.685 1.6873
WSU-DLCL2 GDSC1 0.8236 2.059 -1.3671 0.2857
OCI-M1 GDSC1 0.8476 2.1378 -1.386 0.3271
JVM-2 GDSC1 0.8539 6.734 -3.425 12.8694
LP-1 GDSC1 0.8765 2.4026 -1.4713 0.5913
ATN-1 GDSC1 0.9166 2.5254 -1.5008 0.6744
Raji GDSC1 0.9541 4.2913 -2.2192 4.6961
MC116 GDSC1 0.9585 7.6428 -3.791 14.7729
RL GDSC1 0.9618 2.3992 -1.4362 0.4187
L-363 GDSC1 0.9959 2.9208 -1.6185 1.1084
RC-K8 GDSC1 1.078 2.5266 -1.4375 0.3632
THP-1 GDSC1 1.0856 2.9459 -1.5894 0.899
RPMI-8402 GDSC1 1.1592 8.0466 -3.8476 14.5673
EJM GDSC1 1.1919 2.9473 -1.5459 0.649
LC4-1 GDSC1 1.222 9.2 -4.361 17.1509
H9 GDSC1 1.2644 3.0703 -1.5623 0.6596
Karpas-299 GDSC1 1.3258 2.8692 -1.466 0.33
HH [Human lymphoma] GDSC1 1.3444 7.8544 -3.631 12.8545
HT GDSC1 1.3471 3.103 -1.5415 0.5382
JVM-3 GDSC1 1.3644 3.1495 -1.5517 0.5611
ROS-50 GDSC1 1.4343 6.0419 -2.7291 7.0617
BALL-1 GDSC1 1.4384 10.2072 -4.6977 18.2319
RPMI-8866 GDSC1 1.5183 3.1884 -1.507 0.3551
BC-1 GDSC1 1.5329 8.5816 -3.8521 13.6536
KY821 GDSC1 1.5592 2.7551 -1.3457 0.0654
SK-MM-2 GDSC1 1.6453 3.5297 -1.5804 0.4987
L-1236 GDSC1 1.7673 3.9868 -1.6992 0.8166
RPMI-8226 GDSC1 1.7712 3.4306 -1.4993 0.2485
RS4;11 GDSC1 2.111 11.2449 -4.7365 16.7702
DG-75 GDSC1 2.1955 4.1177 -1.5839 0.2909
Karpas-422 GDSC1 2.8984 13.549 -5.3106 17.5118
⏷ Show the Full List of 149 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-50 GDSC1 -1.4485 -0.4575 -1.684 7.6959
TE-12 GDSC1 -1.0299 1.3384 -2.1717 9.7372
KYSE-220 GDSC1 -0.6575 1.1046 -1.7566 5.2055
HCE-4 GDSC1 -0.6233 1.6543 -2.0025 7.0125
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1 1.5106 3.9519 -1.7942 1.419
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SJNB-7 GDSC1 -1.7813 -0.4275 -2.0443 12.0115
CHP-212 GDSC1 -1.443 -0.4494 -1.6819 7.6534
NB(TU)1 GDSC1 -1.1318 0.9801 -2.0803 9.4067
GI-ME-N GDSC1 -1.0003 2.1612 -2.5581 12.6126
NB69 GDSC1 -0.9312 0.4311 -1.6356 5.1585
SK-N-MC-IXC GDSC1 -0.7412 1.2331 -1.8841 6.4679
SJNB-6 GDSC1 -0.5481 5.5971 -3.9059 20.0364
IMR-5 GDSC1 -0.4697 1.885 -2.0019 6.5358
SJNB-17 GDSC1 -0.3763 2.3598 -2.1665 7.5212
SiMa GDSC1 -0.0167 2.7471 -2.1033 6.0473
MHH-NB-11 GDSC1 0.0332 3.3364 -2.352 7.7534
SJNB-10 GDSC1 0.1597 2.7432 -1.9873 4.7701
SJNB-12 GDSC1 0.1815 3.0878 -2.1347 5.7816
SJNB-5 GDSC1 0.3526 2.8594 -1.9234 3.8998
GOTO GDSC1 0.4325 3.2876 -2.071 4.753
KP-N-YN GDSC1 0.4623 3.8182 -2.2982 6.2824
SJNB-14 GDSC1 0.8056 3.157 -1.8052 2.3374
SK-N-SH GDSC1 0.8219 7.6659 -3.8978 15.7502
KP-N-YS GDSC1 0.8806 6.0911 -3.0995 10.7357
SJNB-13 GDSC1 0.8896 3.4214 -1.8742 2.6216
SK-N-BE(2)-M17 GDSC1 0.9409 2.7031 -1.5581 0.8895
NH-12 GDSC1 0.9883 17.82 -8.784 31.8465
Kelly GDSC1 1.0523 2.4898 -1.4341 0.3658
LA-N-6 GDSC1 1.0608 3.1181 -1.667 1.2717
SK-N-DZ GDSC1 1.1612 2.6133 -1.4369 0.3241
CHP-126 GDSC1 1.1639 8.3835 -4.0067 15.4386
SK-N-FI GDSC1 1.1843 2.8613 -1.5173 0.554
SK-N-AS GDSC1 1.4092 2.8858 -1.4414 0.2417
TGW GDSC1 1.5503 3.1147 -1.4696 0.2561
NB1 GDSC1 2.5783 10.5252 -4.0948 12.5877
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC1 -1.5395 -0.0932 -1.9397 10.0469
Cancer Drug Sensitivity Data Curated from 49 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-85-1 GDSC1 -2.485 -0.1155 -2.9143 21.9055
CAL-120 GDSC1 -1.272 2.3231 -2.8719 15.9952
DU4475 GDSC1 -1.115 1.3589 -2.2546 10.7051
MCF-7 GDSC1 -1.0683 0.1403 -1.6064 5.436
HCC1395 GDSC1 -1.0126 2.53 -2.7529 14.12
CAL-51 GDSC1 -0.9369 0.126 -1.4878 4.0133
JIMT-1 GDSC1 -0.8197 0.5907 -1.6258 4.7
MFM-223 GDSC1 -0.6495 2.1292 -2.2582 9.0818
HCC1428 GDSC1 -0.4592 1.0171 -1.5735 3.2389
HCC38 GDSC1 -0.14 2.797 -2.2114 7.1827
HCC1806 GDSC1 -0.0486 2.9915 -2.242 7.1611
MDA-MB-231 GDSC1 0.2375 2.423 -1.7935 3.244
MRK-nu-1 GDSC1 0.2475 2.471 -1.8093 3.3319
MDA-MB-157 GDSC1 0.2973 5.1094 -3.026 11.8086
Hs 578T GDSC1 0.4778 4.3724 -2.5489 8.0161
MDA-MB-468 GDSC1 0.5888 3.5244 -2.0857 4.5267
MDA-MB-415 GDSC1 0.7134 3.7887 -2.1324 4.5903
CAL-148 GDSC1 0.7659 2.9529 -1.7395 2.0117
ZR-75-30 GDSC1 0.8151 3.3543 -1.8844 2.8003
HCC1599 GDSC1 0.8647 2.6375 -1.5657 0.9927
HDQ-P1 GDSC1 0.9013 3.258 -1.7994 2.1653
Evsa-T GDSC1 0.9905 2.3084 -1.3929 0.282
HCC1500 GDSC1 1.0064 3.0768 -1.6753 1.3692
MDA-MB-361 GDSC1 1.0758 2.5464 -1.4453 0.3869
EFM-19 GDSC1 1.1032 3.8981 -1.9667 2.8479
CAMA-1 GDSC1 1.1065 2.6866 -1.4841 0.4901
OCUB-M GDSC1 1.1595 3.069 -1.605 0.9028
HCC70 GDSC1 1.2112 3.5515 -1.7709 1.6208
MDA-MB-453 GDSC1 1.2388 2.8844 -1.5044 0.4806
BT-20 GDSC1 1.24 3.1829 -1.6144 0.8764
HCC1419 GDSC1 1.2698 2.6577 -1.4127 0.2259
MDA-MB-330 GDSC1 1.2847 7.4355 -3.4714 12.0551
BT-549 GDSC1 1.3345 3.2295 -1.593 0.7238
BT-483 GDSC1 1.3489 2.8152 -1.4387 0.256
HCC2157 GDSC1 1.3598 3.0939 -1.5333 0.5049
UACC-812 GDSC1 1.3843 2.9025 -1.4561 0.2832
HCC1187 GDSC1 1.4088 3.3404 -1.6042 0.714
BT-474 GDSC1 1.4192 2.7203 -1.3815 0.1307
HCC1954 GDSC1 1.5351 3.16 -1.4908 0.3089
HCC1569 GDSC1 1.5761 3.6441 -1.6492 0.7644
COLO 824 GDSC1 1.5979 3.9255 -1.7461 1.1273
HCC1937 GDSC1 1.6229 3.5898 -1.6108 0.6041
UACC-893 GDSC1 1.626 3.5088 -1.5803 0.508
MDA-MB-175-VII GDSC1 1.6379 3.4153 -1.5425 0.3966
MDA-MB-436 GDSC1 1.6966 3.4671 -1.539 0.3633
HCC2218 GDSC1 1.728 3.5822 -1.5679 0.4247
AU565 GDSC1 1.7511 4.2774 -1.8156 1.2917
EFM-192A GDSC1 1.823 3.5727 -1.5297 0.2955
T-47D GDSC1 1.8438 3.9324 -1.6491 0.6027
⏷ Show the Full List of 49 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GB-1 GDSC1 -2.8183 0.6711 -3.5873 28.1291
SF126 GDSC1 -2.4968 0.621 -3.2329 24.1433
T98G GDSC1 -2.355 0.4879 -3.0289 22.0225
D-392MG GDSC1 -2.03 3.3517 -4.0649 26.8375
42-MG-BA GDSC1 -2.0195 1.4625 -3.1405 21.1458
CAS-1 GDSC1 -1.9423 0.6882 -2.7011 17.6457
A-172 GDSC1 -1.7581 0.162 -2.2754 13.6059
8-MG-BA GDSC1 -1.5518 1.1148 -2.5273 14.5825
DBTRG-05MG GDSC1 -1.467 0.4809 -2.14 11.2485
H4 GDSC1 -1.3267 2.8095 -3.1621 18.2712
SW1088 GDSC1 -1.307 6.5601 -5.0167 28.2231
LN-18 GDSC1 -1.2606 -0.1573 -1.6359 6.4594
SF268 GDSC1 -1.2291 0.8573 -2.1051 9.9834
LNZTA3WT4 GDSC1 -1.1265 1.0456 -2.1084 9.6065
ONS-76 GDSC1 -1.0107 0.3012 -1.6371 5.4591
D-502MG GDSC1 -0.935 0.5931 -1.7197 5.8357
Becker GDSC1 -0.9326 0.0544 -1.4485 3.6889
GaMG GDSC1 -0.8892 1.09 -1.9306 7.3351
LN-229 GDSC1 -0.8194 0.6929 -1.6765 5.0972
NMC-G1 GDSC1 -0.7089 0.7489 -1.6196 4.2972
MOG-G-CCM GDSC1 -0.656 1.3156 -1.8597 6.0036
Hs 683 GDSC1 -0.5109 2.1146 -2.1453 7.7665
D-423MG GDSC1 -0.445 1.2547 -1.6777 3.9848
DK-MG GDSC1 -0.4029 7.0641 -4.5218 22.7841
M059J GDSC1 -0.3967 2.0615 -2.0354 6.5778
U-118MG GDSC1 -0.3778 2.5677 -2.2697 8.3121
D-336MG GDSC1 -0.2901 3.7353 -2.7797 11.8372
Daoy GDSC1 -0.2755 1.3987 -1.6342 3.2327
YKG-1 GDSC1 -0.2138 1.5261 -1.6547 3.2368
GI-1 GDSC1 -0.1017 3.8271 -2.6858 10.5816
YH-13 GDSC1 -0.0943 3.3071 -2.4267 8.6603
AM-38 GDSC1 -0.0823 2.1618 -1.8689 4.484
LN-405 GDSC1 -0.0415 2.8305 -2.1598 6.5311
SF539 GDSC1 0.0172 2.662 -2.0404 5.4977
D-542MG GDSC1 0.0726 4.0601 -2.6747 9.9945
KS-1 [Human Krukenberg tumour] GDSC1 0.0947 5.7198 -3.4712 15.3188
D-263MG GDSC1 0.2031 2.3773 -1.7929 3.3094
SF295 GDSC1 0.2199 4.7251 -2.8938 11.1224
U-251MG GDSC1 0.237 2.0208 -1.6159 2.0781
D-247MG GDSC1 0.3007 3.2891 -2.1531 5.6299
SNB-75 GDSC1 0.5157 5.0083 -2.8266 9.8517
D-566MG GDSC1 0.5479 2.7719 -1.7749 2.5578
MOG-G-UVW GDSC1 0.7324 3.1533 -1.8415 2.6699
Onda 11 GDSC1 1.0705 6.9744 -3.394 12.1175
PFSK-1 GDSC1 1.1292 3.2066 -1.6713 1.2231
KNS-42 GDSC1 1.2307 12.5165 -5.9755 23.9681
Onda 10 GDSC1 1.2381 2.8066 -1.4767 0.3981
SK-MG-1 GDSC1 1.2931 2.7272 -1.4284 0.2522
SW1783 GDSC1 1.3485 3.6788 -1.7591 1.4162
U-87MG ATCC GDSC1 1.4785 2.784 -1.3825 0.1204
D283 Med GDSC1 1.512 2.846 -1.3917 0.1271
KNS-81-FD GDSC1 1.8345 3.5762 -1.5267 0.2854
KALS-1 GDSC1 1.8967 3.8242 -1.5905 0.4118
KINGS-1 GDSC1 1.9114 15.3267 -6.8564 25.1407
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1 -0.9446 1.3346 -2.0984 8.8502
TGBC24TKB GDSC1 0.544 2.8229 -1.7991 2.7167
TGBC1TKB GDSC1 1.0977 2.5712 -1.4459 0.3778
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AN3-CA GDSC1 -5.5327 -0.7916 -5.9985 55.1535
MFE-296 GDSC1 -2.8643 2.5761 -4.4911 33.0127
MFE-280 GDSC1 -1.7355 0.7543 -2.5288 15.4065
ESS-1 GDSC1 -1.3986 1.5089 -2.58 14.3359
RL95-2 GDSC1 -0.918 0.3672 -1.5929 4.7751
MFE-319 GDSC1 -0.353 2.1968 -2.07 6.7159
KLE GDSC1 -0.0885 2.7363 -2.1466 6.5579
EN GDSC1 0.8612 2.2084 -1.4062 0.3798
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Caki-1 GDSC1 -2.1095 -0.7624 -2.2749 15.4
786-O GDSC1 -2.0119 -0.4958 -2.263 14.7876
ACHN GDSC1 -1.7942 0.0428 -2.2585 13.653
LB1047-RCC GDSC1 -1.6613 0.168 -2.1813 12.4419
OS-RC-2 GDSC1 -1.2182 0.5945 -1.9651 8.8447
VMRC-RCZ GDSC1 -1.1931 0.6011 -1.9459 8.5938
769-P GDSC1 -1.1316 -0.2055 -1.4917 4.7898
CAL-54 GDSC1 -0.7972 0.9134 -1.7688 5.7481
RCC10RGB GDSC1 -0.7872 0.4517 -1.5317 3.857
SW156 GDSC1 -0.7643 0.8576 -1.7155 5.2219
SN12C GDSC1 -0.6159 1.9697 -2.1531 8.1588
A-704 GDSC1 -0.5853 1.8121 -2.0518 7.2754
LB996-RCC GDSC1 -0.2221 2.4739 -2.1122 6.6648
UO-31 GDSC1 -0.0424 1.7805 -1.6671 2.9462
LB2241-RCC GDSC1 -0.0159 2.4052 -1.9406 4.8477
BFTC-909 GDSC1 0.12 1.917 -1.6345 2.4038
VMRC-RCW GDSC1 0.2542 2.1266 -1.6526 2.2819
RXF 393L GDSC1 0.4289 3.0049 -1.9445 3.8887
TK-10 GDSC1 1.0253 3.1758 -1.7062 1.5029
SW13 GDSC1 1.1103 3.0054 -1.6016 0.9299
BB65-RCC GDSC1 1.1626 3.0673 -1.6031 0.8923
KMRC-1 GDSC1 1.2148 2.774 -1.4739 0.4014
KMRC-20 GDSC1 1.2941 4.7679 -2.2405 4.2127
A-498 GDSC1 1.8259 23.0823 -10.7499 33.3458
HA7-RCC GDSC1 1.842 3.8717 -1.628 0.5398
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KM12 GDSC1 -3.4097 -1.7039 -3.4737 30.9499
HCT 116 GDSC1 -2.1835 0.3608 -2.7971 19.5171
NCI-H747 GDSC1 -1.2863 1.3591 -2.405 12.5419
COLO205 GDSC1 -1.1676 -0.4735 -1.3952 4.196
LoVo GDSC1 -1.0489 0.4785 -1.7583 6.5581
HT-29 GDSC1 -0.9817 -0.1464 -1.3888 3.3943
SW1417 GDSC1 -0.8968 5.6633 -4.223 23.0183
LS180 GDSC1 -0.7635 0.5736 -1.574 4.1124
RKO GDSC1 -0.7608 0.7747 -1.6717 4.8674
NCI-H716 GDSC1 -0.6777 5.9524 -4.1878 22.0419
HCT 15 GDSC1 -0.6411 0.9033 -1.6455 4.2929
SW48 GDSC1 -0.5981 2.6784 -2.4913 10.6955
SW620 GDSC1 -0.593 0.7761 -1.549 3.4124
COLO 678 GDSC1 -0.3509 1.9186 -1.9333 5.6672
SW626 GDSC1 -0.1968 4.2094 -2.9438 12.7125
LS411N GDSC1 -0.1381 6.7784 -4.1716 20.1273
GP5d GDSC1 0.0516 2.4593 -1.9229 4.558
C2BBe1 GDSC1 0.3602 2.2908 -1.667 2.1937
SW837 GDSC1 0.5462 2.6015 -1.7027 2.1179
SNU-C1 GDSC1 0.708 2.5574 -1.6049 1.3496
CCK-81 GDSC1 0.8365 2.6929 -1.6 1.1823
SW1463 GDSC1 0.8397 2.964 -1.7079 1.736
HT-55 GDSC1 0.8455 2.4819 -1.514 0.784
LS123 GDSC1 0.9177 2.4434 -1.4698 0.5578
SNU-C2B GDSC1 0.9496 5.5345 -2.792 8.5397
T84 GDSC1 0.9756 3.2072 -1.7422 1.7498
COLO 320HSR GDSC1 0.9786 3.1531 -1.7188 1.6224
LS1034 GDSC1 1.0414 2.5473 -1.4589 0.4463
SW948 GDSC1 1.075 10.1974 -4.9515 20.3418
CL-11 GDSC1 1.1526 3.3511 -1.7178 1.421
HT115 GDSC1 1.1542 2.3423 -1.3459 0.1327
MDST8 GDSC1 1.2516 2.6548 -1.4183 0.2441
CaR-1 GDSC1 1.3444 3.3113 -1.6195 0.8166
RCM-1 [Human ESC] GDSC1 1.4957 2.9708 -1.4397 0.2119
HCC2998 GDSC1 1.5086 3.1243 -1.4881 0.3124
LS513 GDSC1 1.5769 3.2314 -1.5005 0.3162
CW-2 GDSC1 1.7454 3.6156 -1.5732 0.4312
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1 1.6855 3.0713 -1.4076 0.1169
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hep 3B2.1-7 GDSC1 -3.7161 -2.1518 -3.7453 34.5578
JHH-7 GDSC1 -2.1351 -0.0947 -2.5526 17.5096
SNU-398 GDSC1 -1.8954 4.6634 -4.5883 28.7854
Huh-7 GDSC1 -1.8034 1.2133 -2.8133 17.8248
JHH-4 GDSC1 -1.7861 0.9079 -2.6509 16.5489
SNU-449 GDSC1 -1.6898 -0.3408 -1.9841 11.1074
SK-HEP-1 GDSC1 -1.5198 -0.1969 -1.8727 9.4492
HLE GDSC1 -1.3029 1.5067 -2.4932 13.2853
Hep-G2/C3A GDSC1 -1.0108 -0.1758 -1.3989 3.5825
SNU-387 GDSC1 -0.9637 0.8699 -1.8819 7.2164
HuH-1 GDSC1 -0.5798 1.3666 -1.828 5.5227
JHH-1 GDSC1 -0.4206 1.1523 -1.6122 3.4289
SNU-423 GDSC1 0.0265 2.2259 -1.83 3.9475
SNU-475 GDSC1 0.4342 2.8537 -1.8735 3.3997
JHH-6 GDSC1 0.6278 1.8165 -1.3548 0.3465
JHH-2 GDSC1 1.9572 3.6026 -1.4923 0.1869
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 168 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2369 GDSC1 -3.8337 -1.1233 -4.0541 37.0491
NCI-H2795 GDSC1 -2.9012 -1.389 -2.9793 24.6935
NCI-H520 GDSC1 -2.408 -0.7542 -2.6022 19.3179
NCI-H2818 GDSC1 -2.378 1.679 -3.5929 25.8306
NCI-H1703 GDSC1 -2.3452 1.5403 -3.4958 25.0663
A-427 GDSC1 -2.2902 0.9888 -3.1866 22.7748
NCI-H2342 GDSC1 -2.2621 0.3334 -2.8661 20.4054
NCI-H2087 GDSC1 -2.2348 -0.032 -2.6833 18.9614
LC-2/ad GDSC1 -2.2277 11.4624 -8.2604 39.5278
HOP-62 GDSC1 -1.7162 0.506 -2.3928 14.2941
NCI-H2030 GDSC1 -1.6277 5.5571 -4.794 28.5587
SK-LU-1 GDSC1 -1.5401 0.4835 -2.2111 12.1167
LCLC-97TM1 GDSC1 -1.2921 1.2479 -2.3551 12.1799
NCI-H2869 GDSC1 -1.1731 1.1279 -2.1901 10.4261
NCI-H727 GDSC1 -1.1332 1.1649 -2.1737 10.143
NCI-H2009 GDSC1 -1.1292 0.2259 -1.7027 6.432
NCI-H1755 GDSC1 -1.0853 0.3678 -1.7346 6.5103
NCI-H3122 GDSC1 -1.0361 0.4647 -1.7404 6.3689
LCLC-103H GDSC1 -1.0327 0.5786 -1.7944 6.7814
NCI-H460 GDSC1 -1.0241 -0.1834 -1.4066 3.6933
NCI-H2731 GDSC1 -0.9871 3.7736 -3.3533 18.2334
HCC44 GDSC1 -0.9239 0.823 -1.8255 6.6298
IA-LM GDSC1 -0.9164 0.8755 -1.8456 6.7611
NCI-H1975 GDSC1 -0.8866 0.6904 -1.7288 5.7369
COR-L105 GDSC1 -0.8835 1.4203 -2.0909 8.5742
NCI-H2803 GDSC1 -0.8749 1.5931 -2.1703 9.1656
HOP-92 GDSC1 -0.8655 2.8522 -2.7918 13.8665
NCI-H810 GDSC1 -0.8525 2.9361 -2.8231 14.0488
IST-SL2 GDSC1 -0.8393 10.1374 -6.4123 31.292
NCI-H292 GDSC1 -0.8325 0.6329 -1.657 4.987
LXF 289 GDSC1 -0.8308 0.9394 -1.8084 6.1721
Lu-99A GDSC1 -0.8184 1.4489 -2.0526 8.048
NCI-H1792 GDSC1 -0.785 0.6371 -1.622 4.5565
NCI-H1299 GDSC1 -0.7808 0.5268 -1.5641 4.0899
CAL-12T GDSC1 -0.7645 1.5496 -2.0599 7.9214
NCI-H2347 GDSC1 -0.7492 2.5263 -2.5348 11.5371
SK-MES-1 GDSC1 -0.7342 0.8771 -1.7021 5.02
NCI-H2405 GDSC1 -0.7324 1.2305 -1.876 6.3754
SW1271 GDSC1 -0.7265 1.5011 -2.006 7.3734
NCI-H522 GDSC1 -0.7222 1.9762 -2.239 9.1748
Calu-6 GDSC1 -0.7051 0.7284 -1.6067 4.1855
NCI-H226 GDSC1 -0.6593 1.0751 -1.7434 5.1079
SBC-3 GDSC1 -0.6507 2.4005 -2.394 10.13
DMS 273 GDSC1 -0.6312 1.7719 -2.0668 7.5376
PC-14 GDSC1 -0.6034 1.1117 -1.7202 4.7589
EBC-1 GDSC1 -0.5845 1.3726 -1.8345 5.5872
HARA [Human squamous cell lung carcinoma] GDSC1 -0.5829 1.2798 -1.7876 5.2195
NCI-H1944 GDSC1 -0.5781 1.1648 -1.7278 4.7428
NCI-H2085 GDSC1 -0.5647 1.5692 -1.9165 6.1628
NCI-H1568 GDSC1 -0.5494 2.0704 -2.1524 7.942
NCI-H358 GDSC1 -0.545 4.5226 -3.3677 16.734
NCI-H2591 GDSC1 -0.5347 1.9567 -2.0852 7.3763
A-549 GDSC1 -0.5181 0.8168 -1.5173 2.9703
NCI-H1048 GDSC1 -0.4682 1.5147 -1.8198 5.132
NCI-H1734 GDSC1 -0.4523 3.3298 -2.7021 11.7909
COLO 668 GDSC1 -0.4502 2.5632 -2.3212 8.927
NCI-H647 GDSC1 -0.4016 1.6323 -1.8299 5.0219
RERF-LC-KJ GDSC1 -0.3973 1.4842 -1.7555 4.4452
NCI-H1651 GDSC1 -0.3398 3.5532 -2.7272 11.6135
LOU-NH91 GDSC1 -0.282 2.0053 -1.9273 5.4324
NCI-H2228 GDSC1 -0.2752 1.7772 -1.8132 4.5561
NCI-H1869 GDSC1 -0.2485 2.4219 -2.1055 6.6874
NCI-H1581 GDSC1 -0.2377 3.8624 -2.8032 11.8422
NCI-H1563 GDSC1 -0.2299 1.4923 -1.6491 3.2341
NCI-H1770 GDSC1 -0.2143 3.7473 -2.7291 11.2359
EPLC-272H GDSC1 -0.1771 4.0012 -2.8266 11.8218
Calu-3 GDSC1 -0.1754 2.3872 -2.038 5.9785
NCI-H2170 GDSC1 -0.1609 8.4218 -5.0069 24.199
SW1573 GDSC1 -0.1466 2.4455 -2.0464 5.9645
LK-2 GDSC1 -0.1385 2.1582 -1.9038 4.8805
NCI-H1650 GDSC1 -0.1257 1.8519 -1.7512 3.7302
Ms-1 GDSC1 -0.0553 2.9213 -2.2128 6.9622
NCI-H1793 GDSC1 -0.0044 3.8989 -2.6509 10.044
NCI-H1355 GDSC1 0.0026 2.1456 -1.8076 3.8414
Lu-135 GDSC1 0.0161 2.0363 -1.7489 3.3948
NCI-H3255 GDSC1 0.0554 1.8792 -1.6544 2.66
COR-L23 GDSC1 0.0713 1.7887 -1.6049 2.2991
NCI-H69 GDSC1 0.1177 8.002 -4.5818 21.3947
NCI-H2110 GDSC1 0.1341 2.0368 -1.6798 2.6785
NCI-H1688 GDSC1 0.158 3.0909 -2.1515 5.9605
NCI-H838 GDSC1 0.18 3.5785 -2.3686 7.4852
ChaGo-K-1 GDSC1 0.2125 2.6335 -1.9041 4.061
NCI-H209 GDSC1 0.2189 3.3285 -2.2241 6.337
NCI-H650 GDSC1 0.2463 2.1321 -1.6594 2.3389
NCI-H211 GDSC1 0.2558 3.3836 -2.2262 6.2618
NCI-H1435 GDSC1 0.3467 1.9829 -1.5433 1.4744
NCI-H1915 GDSC1 0.3605 2.5391 -1.7753 2.8876
NCI-H290 GDSC1 0.4097 2.1899 -1.5984 1.7029
COR-L88 GDSC1 0.4197 4.6532 -2.7213 9.3749
NCI-H1304 GDSC1 0.4291 4.0394 -2.4233 7.2482
NCI-H2196 GDSC1 0.4472 2.5804 -1.7458 2.544
NCI-H1993 GDSC1 0.4474 2.4663 -1.6964 2.2344
IST-SL1 GDSC1 0.4637 2.5971 -1.7443 2.5062
NCI-H2595 GDSC1 0.4678 2.8742 -1.8637 3.2707
NCI-H441 GDSC1 0.5004 3.3747 -2.0701 4.6024
NCI-H526 GDSC1 0.5035 4.7712 -2.7215 9.1579
NCI-H2722 GDSC1 0.5234 2.0847 -1.5007 1.0302
NCI-H2444 GDSC1 0.5679 2.3444 -1.5847 1.4128
NCI-H187 GDSC1 0.5997 1.9153 -1.4023 0.5288
NCI-H1836 GDSC1 0.602 2.0629 -1.4574 0.7514
ABC-1 GDSC1 0.622 2.6119 -1.6688 1.8083
BEN GDSC1 0.6368 2.8713 -1.7708 2.3887
NCI-H1648 GDSC1 0.6454 2.9638 -1.8059 2.5909
NCI-H345 GDSC1 0.6856 1.6853 -1.2871 0.1489
Lu-165 GDSC1 0.7032 5.8053 -3.0817 11.0753
NCI-H596 GDSC1 0.7799 2.2283 -1.4456 0.5636
NCI-H322M GDSC1 0.7811 3.0413 -1.7689 2.1602
NCI-H841 GDSC1 0.7951 2.5977 -1.581 1.1336
NCI-H2804 GDSC1 0.8254 3.5707 -1.9726 3.3338
DMS 79 GDSC1 0.8318 3.1285 -1.78 2.1516
NCI-H2135 GDSC1 0.8361 2.402 -1.4877 0.6839
DMS 53 GDSC1 0.8717 4.0713 -2.168 4.517
NCI-H510A GDSC1 0.8721 2.7333 -1.6 1.145
NCI-H1694 GDSC1 0.8835 2.6963 -1.5804 1.0419
HCC78 GDSC1 0.8877 3.6414 -1.9697 3.2098
NCI-H2373 GDSC1 0.896 2.5649 -1.5243 0.785
NCI-H1092 GDSC1 0.9053 2.7505 -1.5919 1.0741
NCI-H1436 GDSC1 0.9176 2.6812 -1.5597 0.917
NCI-H2122 GDSC1 0.9316 3.0949 -1.7174 1.6719
NCI-H720 GDSC1 0.9712 2.3373 -1.4104 0.3373
NCI-H748 GDSC1 0.9721 11.4303 -5.6323 23.4006
NCI-H82 GDSC1 0.9757 2.7338 -1.555 0.847
NCI-H196 GDSC1 0.9768 5.4194 -2.7212 8.0035
NCI-H2227 GDSC1 0.9791 2.9944 -1.655 1.2988
NCI-H446 GDSC1 0.9836 4.5368 -2.3124 5.2536
NCI-H524 GDSC1 0.9898 3.2497 -1.7528 1.7891
NCI-H1693 GDSC1 0.9975 2.9377 -1.6244 1.1342
NCI-H1876 GDSC1 1.0427 2.5714 -1.4671 0.4717
NCI-H2141 GDSC1 1.0605 2.4797 -1.4274 0.3431
NCI-H2291 GDSC1 1.108 3.098 -1.6383 1.0921
SBC-5 GDSC1 1.1185 2.1833 -1.305 0.0816
NCI-H1781 GDSC1 1.1219 2.7887 -1.5154 0.5865
Lu-65 GDSC1 1.2244 2.9503 -1.534 0.5862
NCI-H1573 GDSC1 1.239 2.8326 -1.4857 0.4237
COR-L95 GDSC1 1.2499 2.9056 -1.5077 0.485
NCI-H2171 GDSC1 1.2503 2.6158 -1.4053 0.2165
SHP-77 GDSC1 1.254 3.3958 -1.6902 1.1895
NCI-H2023 GDSC1 1.2623 5.8942 -2.7647 7.6545
LB647-SCLC GDSC1 1.2643 3.0086 -1.5396 0.5806
NCI-H1437 GDSC1 1.2657 3.122 -1.581 0.7269
NCI-H1838 GDSC1 1.285 3.8639 -1.8625 2.009
NCI-H1963 GDSC1 1.2861 3.0739 -1.5549 0.6195
NCI-H2081 GDSC1 1.29 3.3702 -1.6647 1.0446
NCI-H2172 GDSC1 1.3019 2.7848 -1.4452 0.288
UMC-11 GDSC1 1.3081 3.1067 -1.5582 0.6172
NCI-H847 GDSC1 1.3305 2.6895 -1.402 0.1864
PaCa-3 GDSC1 1.4074 3.6223 -1.7113 1.1426
NCI-H1666 GDSC1 1.4135 3.3025 -1.5883 0.6547
NCI-H2029 GDSC1 1.4159 2.6927 -1.3734 0.1196
SBC-1 GDSC1 1.4496 8.2739 -3.7609 13.344
HCC33 GDSC1 1.4565 3.3991 -1.6067 0.6914
RERF-LC-Sq1 GDSC1 1.4678 4.0009 -1.8327 1.646
HCC827 GDSC1 1.4867 3.1587 -1.5083 0.3716
Lu-139 GDSC1 1.5009 3.2401 -1.5318 0.4291
DMS 114 GDSC1 1.5141 3.7378 -1.71 1.0464
RERF-LC-MS GDSC1 1.534 3.1046 -1.472 0.2666
NCI-H1155 GDSC1 1.6246 3.1248 -1.4467 0.19
NCI-H513 GDSC1 1.6641 3.2938 -1.4905 0.2637
CPC-N GDSC1 1.7082 3.5359 -1.5589 0.4095
NCI-H23 GDSC1 1.7134 3.7767 -1.6434 0.6579
NCI-H661 GDSC1 1.7839 3.4909 -1.5155 0.2779
NCI-H1623 GDSC1 1.8035 3.7202 -1.5885 0.4466
NCI-H64 GDSC1 1.8683 12.096 -5.3121 19.8579
LC-1/sq GDSC1 2.131 4.342 -1.6862 0.5663
HCC15 GDSC1 2.133 3.8255 -1.5066 0.1709
Lu-134-A GDSC1 2.2011 4.6315 -1.7636 0.7672
NCI-H2461 GDSC1 2.4013 4.5784 -1.669 0.4072
EKVX GDSC1 2.6541 4.868 -1.678 0.3419
⏷ Show the Full List of 168 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1 1.0681 10.05 -4.8844 20.061
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE-15 GDSC1 -1.9202 0.33 -2.515 16.1668
KYSE-180 GDSC1 -1.8785 -0.1996 -2.2404 13.935
KYSE-150 GDSC1 -1.7415 -0.175 -2.1087 12.283
KYSE-410 GDSC1 -1.4325 -0.2773 -1.7483 8.0992
KYSE-450 GDSC1 -1.277 0.4343 -1.9395 8.8854
T.T GDSC1 -1.1839 -0.3078 -1.4905 5.0023
KYSE-140 GDSC1 -1.093 0.5431 -1.8287 7.2802
TE-9 GDSC1 -1.0267 -0.2025 -1.3993 3.6456
KYSE-520 GDSC1 -1.0262 0.724 -1.8616 7.286
KYSE-510 GDSC1 -0.8908 0.5194 -1.6469 5.106
KYSE-270 GDSC1 -0.8686 1.2391 -1.9883 7.7168
KYSE-70 GDSC1 -0.8449 0.2878 -1.495 3.7559
OE21 GDSC1 -0.7305 1.0782 -1.7989 5.7656
TE-11 GDSC1 -0.6392 0.8805 -1.6329 4.19
COLO 680N GDSC1 -0.5158 2.0843 -2.134 7.6951
TE-10 GDSC1 -0.463 1.0993 -1.6153 3.5622
TE-6 GDSC1 -0.0032 2.2004 -1.8367 4.0631
TE-5 GDSC1 0.7233 2.464 -1.5606 1.1099
OE33 GDSC1 1.2138 3.3076 -1.6735 1.1516
OE19 GDSC1 1.3289 2.6581 -1.3919 0.1685
EC-GI-10 GDSC1 1.4551 3.2287 -1.5452 0.4907
TE-8 GDSC1 1.4756 8.4665 -3.8353 13.7
TE-1 GDSC1 1.5722 3.2381 -1.5045 0.3276
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TOV-112D GDSC1 -1.9199 -0.4979 -2.1639 13.5942
Kuramochi GDSC1 -1.7936 0.8883 -2.6488 16.5675
OVTOKO GDSC1 -1.7105 0.3573 -2.3177 13.7006
A2780 GDSC1 -1.557 1.6969 -2.8171 16.7687
EFO-27 GDSC1 -1.2397 0.1555 -1.7684 7.3969
EFO-21 GDSC1 -1.2341 1.2645 -2.3117 11.6127
OVCAR-4 GDSC1 -1.2284 3.7491 -3.5455 20.4017
SK-OV-3 GDSC1 -0.9846 -0.0831 -1.4229 3.6743
FU-OV-1 GDSC1 -0.9288 1.5973 -2.2167 9.719
OAW42 GDSC1 -0.4389 1.6163 -1.8484 5.2674
OVCAR-3 GDSC1 -0.4079 1.2994 -1.6739 3.8582
OVCAR-8 GDSC1 -0.3588 1.2072 -1.5976 3.166
OVCAR-5 GDSC1 -0.3211 2.8069 -2.3456 8.7169
TOV-21G GDSC1 -0.3108 1.7161 -1.808 4.6105
OVISE GDSC1 0.1062 2.264 -1.7989 3.5522
OAW28 GDSC1 0.1237 2.1206 -1.7233 2.9934
OC 314 GDSC1 0.228 3.1554 -2.1368 5.6843
OVKATE GDSC1 0.2627 2.1431 -1.6552 2.2835
TYK-nu GDSC1 1.2291 2.8864 -1.5089 0.5002
Caov-3 GDSC1 1.2537 3.0161 -1.5466 0.6111
ES-2 GDSC1 1.2577 2.9756 -1.5302 0.5528
RMG-I GDSC1 1.2785 3.5369 -1.7346 1.371
OV-90 GDSC1 1.6632 3.5471 -1.5798 0.488
Caov-4 GDSC1 2.2682 4.4833 -1.6847 0.4994
IGROV-1 GDSC1 2.3108 4.2165 -1.5768 0.2451
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MZ-PC-1 GDSC1 -3.1007 1.2726 -4.1383 32.7341
BxPC-3 GDSC1 -1.7823 0.1159 -2.2791 13.7488
SUIT-2 GDSC1 -1.6673 -0.5886 -1.8595 10.0867
PaTu 8988t GDSC1 -0.9587 0.5484 -1.717 5.8984
Panc 08.13 GDSC1 -0.9191 16.4472 -9.6334 37.7175
KP-3 GDSC1 -0.9164 1.0288 -1.9222 7.3645
CFPAC-1 GDSC1 -0.894 1.9319 -2.3553 10.6711
Panc 03.27 GDSC1 -0.8567 0.2402 -1.4805 3.6808
Capan-1 GDSC1 -0.3604 1.5082 -1.7419 4.244
SW1990 GDSC1 -0.3065 1.4664 -1.6861 3.6899
Hs 766T GDSC1 -0.2335 2.2676 -2.0204 6.0032
KP-2 GDSC1 -0.2147 2.491 -2.1153 6.6672
KP-1N GDSC1 -0.0486 2.8062 -2.153 6.4994
HPAF-II GDSC1 -0.0199 9.9589 -5.6613 26.3324
HPAC GDSC1 0.0181 3.3556 -2.3716 7.9391
MIA PaCa-2 GDSC1 0.1414 8.7515 -4.9354 22.9457
PL4 GDSC1 0.3317 2.2134 -1.6487 2.1265
Capan-2 GDSC1 0.3518 2.8394 -1.9148 3.8426
AsPC-1 GDSC1 0.4488 3.0838 -1.9685 4.0123
HuP-T4 GDSC1 0.524 2.1631 -1.5318 1.1867
Panc 02.03 GDSC1 0.5616 2.3347 -1.5837 1.4155
YAPC GDSC1 0.6628 1.9477 -1.3889 0.4379
Panc 10.05 GDSC1 0.7266 2.5618 -1.5981 1.2929
KP-4 GDSC1 0.9595 2.1574 -1.3516 0.1965
SU.86.86 GDSC1 1.0994 2.5879 -1.4513 0.3925
PSN1 GDSC1 1.2259 2.8765 -1.5065 0.4944
DAN-G GDSC1 1.2692 2.9085 -1.5013 0.455
PaTu 8902 GDSC1 1.2694 2.7462 -1.4436 0.2967
Panc 04.03 GDSC1 1.2902 3.0425 -1.5418 0.5723
HuP-T3 GDSC1 1.7826 3.7148 -1.5944 0.4725
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MPP 89 GDSC1 -2.4494 0.6295 -3.1878 23.5943
NCI-H2052 GDSC1 -1.5097 3.0815 -3.4588 20.998
IST-Mes1 GDSC1 -1.3133 10.5179 -6.9997 34.3051
NCI-H28 GDSC1 0.3763 2.5868 -1.7876 2.9393
NCI-H2452 GDSC1 0.8986 11.1193 -5.5337 23.2235
MSTO-211H GDSC1 1.7181 3.4592 -1.5283 0.3293
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU145 GDSC1 -0.8681 1.7629 -2.2496 9.7595
LNCaP clone FGC GDSC1 1.7557 8.0121 -3.4402 10.7652
VCaP GDSC1 1.7663 3.3416 -1.4706 0.1962
22Rv1 GDSC1 1.9817 3.7833 -1.5453 0.2777
PC-3 GDSC1 2.2475 4.2334 -1.6051 0.3182
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1 1.3531 10.8104 -5.0511 20.0451
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
G-mel GDSC1 -2.0377 0.3822 -2.6576 17.786
WM278 GDSC1 -1.9127 0.0521 -2.3838 15.16
CHL-1 GDSC1 -1.849 -0.5197 -2.0798 12.6198
HT-144 GDSC1 -1.7364 0.6724 -2.4909 15.1258
WM1552C GDSC1 -1.6596 0.1733 -2.182 12.4391
451Lu GDSC1 -1.4969 -0.3595 -1.7767 8.6211
WM793 GDSC1 -1.4422 1.0717 -2.4045 13.1783
Mel JuSo GDSC1 -1.4367 -0.195 -1.7902 8.4355
SK-MEL-24 GDSC1 -1.3132 1.6799 -2.5883 14.0505
A-431 GDSC1 -1.2578 0.0996 -1.7578 7.3909
WM35 GDSC1 -1.2562 0.7778 -2.0901 9.975
IST-MEL1 GDSC1 -1.1364 1.0083 -2.0984 9.5663
Mel Ho GDSC1 -1.041 2.4979 -2.7607 14.2844
LOX-IMVI GDSC1 -0.98 0.044 -1.4826 4.1281
SH-4 GDSC1 -0.9753 1.0738 -1.9935 8.1376
SK-MEL-2 GDSC1 -0.8736 4.2715 -3.5081 18.8091
G-361 GDSC1 -0.8546 0.9202 -1.8178 6.3272
A-375 GDSC1 -0.8473 0.3513 -1.5284 4.0261
A101D GDSC1 -0.8343 0.8754 -1.7792 5.9544
IPC-298 GDSC1 -0.828 0.1168 -1.397 2.9334
COLO 679 GDSC1 -0.791 0.9137 -1.7641 5.6904
SK-MEL-3 GDSC1 -0.7146 0.9475 -1.722 5.1141
MMAc-SF GDSC1 -0.708 0.9112 -1.6991 4.9143
SK-MEL-28 GDSC1 -0.6827 1.8136 -2.1272 8.1744
IGR-1 GDSC1 -0.6275 0.8031 -1.5866 3.799
SK-MEL-30 GDSC1 -0.5746 0.9615 -1.6261 3.95
RVH-421 GDSC1 -0.3957 1.1837 -1.6107 3.3541
A2058 GDSC1 -0.3889 0.9264 -1.4853 2.4184
HMV-II GDSC1 -0.3844 2.8426 -2.4098 9.3951
MZ-MEL-7 GDSC1 -0.3145 1.969 -1.9322 5.5584
Hs 938.T GDSC1 -0.2352 2.9312 -2.3441 8.4506
VMRC-MELG GDSC1 -0.0787 4.2319 -2.8675 11.8123
UACC-62 GDSC1 -0.0236 3.436 -2.4395 8.5546
IGR-37 GDSC1 0.1481 3.6923 -2.4447 8.1224
A-388 GDSC1 0.4262 3.2693 -2.0664 4.7351
SK-MEL-5 GDSC1 0.5249 1.8601 -1.4126 0.6269
GAK GDSC1 0.5909 1.9929 -1.4353 0.6666
WT2-iPS GDSC1 0.872 2.3653 -1.4592 0.5503
LB373-MEL-D GDSC1 0.8886 3.6532 -1.9744 3.2378
SK-MEL-1 GDSC1 0.96 2.2875 -1.3969 0.3055
COLO 783 GDSC1 0.9622 2.4092 -1.4396 0.4292
WM115 GDSC1 0.9699 2.4242 -1.4421 0.4327
RPMI-7951 GDSC1 0.9785 2.5117 -1.4707 0.5218
CP66-MEL GDSC1 0.9792 2.4304 -1.4407 0.4232
M14 GDSC1 1.005 2.8365 -1.5818 0.9361
UACC-257 GDSC1 1.082 2.9665 -1.5988 0.9419
Hs 940.T GDSC1 1.1571 3.0114 -1.5842 0.8199
MeWo GDSC1 1.171 2.8805 -1.5296 0.6047
COLO 792 GDSC1 1.2105 4.5249 -2.1798 3.9775
MZ-MEL-2 GDSC1 1.2704 12.0665 -5.7252 22.9647
LB2518-MEL GDSC1 1.285 2.6478 -1.4039 0.2032
CP50-MEL-B GDSC1 1.3233 2.7604 -1.4289 0.2433
COLO 800 GDSC1 1.3965 2.8645 -1.4385 0.2399
DJM-1 GDSC1 1.615 3.3337 -1.5223 0.3544
COLO 829 GDSC1 4.381 22.1747 -8.4402 24.3531
EquiPSC Line K2 GDSC1 1.5207 3.9567 -1.7916 1.3971
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 -0.9076 1.3472 -2.0741 8.5277
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-204 GDSC1 -6.1731 -2.055 -6.3927 61.7427
G-402 GDSC1 -4.0327 -0.419 -4.4766 40.298
STS-0421 GDSC1 -3.2927 -0.9114 -3.5203 30.5113
SK-LMS-1 GDSC1 -1.7764 1.2435 -2.8019 17.6192
SW982 GDSC1 -1.7301 0.0874 -2.2135 13.0088
MES-SA GDSC1 -1.7153 -0.2287 -2.0584 11.7821
Hs 633.T GDSC1 -1.6847 -0.5616 -1.8885 10.3866
MFH-ino GDSC1 -1.174 0.7946 -2.025 9.1377
SW872 GDSC1 -1.0533 0.3453 -1.6956 6.0813
SK-UT-1 GDSC1 -1.014 0.0767 -1.5277 4.6092
GCT GDSC1 -0.9606 0.2483 -1.5685 4.7347
VA-ES-BJ GDSC1 -0.9478 0.2495 -1.5585 4.6098
G-401 GDSC1 -0.6766 3.1541 -2.79 13.1866
TE 441.T GDSC1 -0.6114 1.9068 -2.1185 7.8757
HT-1080 GDSC1 -0.549 6.9936 -4.6037 23.6718
Rh41 GDSC1 -0.1931 3.2831 -2.4857 9.385
Rh30 GDSC1 0.6447 5.3267 -2.8923 9.9643
KYM-1 GDSC1 0.7685 2.3749 -1.5059 0.815
RD GDSC1 0.9088 2.9663 -1.676 1.4826
SW684 GDSC1 1.0338 2.3005 -1.3743 0.2212
EW-8 GDSC1 1.051 2.4928 -1.4356 0.3709
RKN GDSC1 1.0529 2.6262 -1.4831 0.5186
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HGC-27 GDSC1 -1.8648 -0.2235 -2.216 13.6881
RERF-GC-1B GDSC1 -1.7825 3.2866 -3.8058 24.2889
Fu97 GDSC1 -1.2373 0.9469 -2.1569 10.4202
ECC12 GDSC1 -0.9655 0.7304 -1.8136 6.6849
RF-48 GDSC1 -0.9343 2.9871 -2.916 15.0208
IM95 GDSC1 -0.8176 1.0718 -1.8639 6.5633
ECC10 GDSC1 -0.7906 4.9764 -3.7922 20.2396
MKN28 GDSC1 -0.6275 1.1396 -1.7516 5.0742
SNU-1 GDSC1 -0.6184 1.6715 -2.0073 7.0347
HSC-39 GDSC1 -0.5318 2.345 -2.2749 8.8294
AGS GDSC1 -0.2162 2.4959 -2.1187 6.6972
NUGC-4 GDSC1 -0.122 2.7338 -2.1684 6.8112
MKN1 GDSC1 0.0179 3.3757 -2.3815 8.0125
SNU-16 GDSC1 0.4448 2.1175 -1.5509 1.3858
MKN7 GDSC1 0.919 6.4269 -3.2339 11.5015
Hs 746.T GDSC1 0.9843 2.656 -1.5219 0.7061
SNU-5 GDSC1 1.0164 2.7414 -1.5408 0.7559
GCIY GDSC1 1.137 3.4681 -1.7719 1.7111
NUGC-3 GDSC1 1.1424 2.9941 -1.5838 0.8298
TMK-1 GDSC1 1.1426 3.4593 -1.7657 1.6725
OCUM-1 GDSC1 1.2244 3.1516 -1.6091 0.8673
MKN45 GDSC1 1.2638 12.1278 -5.7601 23.1106
NCI-N87 GDSC1 1.2961 3.893 -1.8691 2.0305
SCH GDSC1 1.2991 2.6384 -1.3957 0.1833
TGBC11TKB GDSC1 1.3329 3.1728 -1.5727 0.6516
23132/87 GDSC1 1.681 3.1657 -1.4409 0.1665
SNG-M GDSC1 -0.9769 0.6377 -1.7768 6.4368
⏷ Show the Full List of 27 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CGTH-W-1 GDSC1 -8.0924 -5.0755 -8.1076 81.8865
TT2609-C02 GDSC1 -2.0264 -0.6462 -2.224 14.5897
IHH-4 GDSC1 -1.7436 -0.5031 -1.9742 11.3099
ML-1 [Human leukemia] GDSC1 -1.6745 0.4837 -2.3415 13.7145
B-CPAP GDSC1 -1.5375 1.4933 -2.6992 15.8134
8305C GDSC1 -1.4229 0.5828 -2.1477 11.117
HTC-C3 GDSC1 -1.1488 0.4667 -1.8398 7.5855
WRO GDSC1 -1.0519 1.262 -2.1523 9.6668
8505C GDSC1 -0.875 0.9826 -1.8654 6.7719
K5 GDSC1 -0.7973 0.8537 -1.7392 5.5161
BHT-101 GDSC1 -0.5985 1.9814 -2.1456 8.0445
CAL-62 GDSC1 -0.0744 1.4595 -1.5408 2.147
ASH-3 GDSC1 0.3869 1.8968 -1.4885 1.1229
FTC-133 GDSC1 1.2962 2.4417 -1.3305 0.0845
TT GDSC1 1.4755 3.2236 -1.5355 0.4518
KMH-2 GDSC1 1.575 3.2611 -1.5116 0.3437
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PCI-06A GDSC1 -1.5914 0.0446 -2.0547 11.1587
NCI-H3118 GDSC1 -1.4272 -0.087 -1.831 8.7019
KON GDSC1 -1.1521 0.4707 -1.8447 7.637
BHY GDSC1 -1.1149 -0.0632 -1.5466 5.1511
HSC-2 GDSC1 -1.0184 0.0592 -1.5228 4.5873
PCI-04B GDSC1 -0.9575 0.4714 -1.6775 5.5828
JHU-011 GDSC1 -0.9554 1.0263 -1.9532 7.7484
OSC-20 GDSC1 -0.9385 0.3835 -1.6179 5.0448
JHU-029 GDSC1 -0.9031 1.6632 -2.2284 9.7189
KOSC-2 GDSC1 -0.8139 1.475 -2.062 8.106
BB30-HNC GDSC1 -0.7638 1.0227 -1.7971 5.8604
SCC-25 GDSC1 -0.7331 1.914 -2.2167 9.038
UPCI-SCC-090 GDSC1 -0.7231 1.2189 -1.8631 6.2441
LB771-HNC GDSC1 -0.6749 5.2128 -3.8162 19.9642
BICR 31 GDSC1 -0.6228 0.9598 -1.6598 4.3495
HSC-3 GDSC1 -0.5845 1.5205 -1.9073 6.1515
HSC-4 GDSC1 -0.5292 0.8621 -1.5465 3.2192
SCC-9 GDSC1 -0.4629 1.5211 -1.8191 5.1112
DOK GDSC1 -0.2609 2.2748 -2.0429 6.2483
SCC-4 GDSC1 -0.2065 1.6516 -1.7087 3.6121
Detroit 562 GDSC1 -0.1091 1.6162 -1.632 2.8423
PCI-15A GDSC1 0.1379 2.2625 -1.7792 3.3487
JHU-022 GDSC1 0.1597 2.4175 -1.8369 3.7037
Ca9-22 GDSC1 0.2749 3.9768 -2.4952 8.1524
PCI-38 GDSC1 0.4877 2.8034 -1.8213 2.9567
CAL-33 GDSC1 0.6641 2.5682 -1.6301 1.5368
HO-1-u-1 GDSC1 0.7412 2.4934 -1.5641 1.1084
CAL-27 GDSC1 0.8485 2.3204 -1.4521 0.5402
BICR 78 GDSC1 0.8613 2.6846 -1.5856 1.088
SCC-15 GDSC1 1.0992 2.9837 -1.598 0.924
BICR 22 GDSC1 1.1722 3.0239 -1.5826 0.8019
PE/CA-PJ15 GDSC1 1.2085 2.8556 -1.5057 0.5017
BICR 10 GDSC1 1.2178 3.1763 -1.6213 0.9224
SAS GDSC1 1.2238 3.3661 -1.6919 1.2258
OSC-19 GDSC1 1.2835 3.1763 -1.594 0.7631
FaDu GDSC1 1.4884 2.9108 -1.4218 0.1806
PCI-30 GDSC1 1.5027 3.179 -1.5095 0.368
BB49-HNC GDSC1 1.538 3.4942 -1.6093 0.6492
HO-1-N-1 GDSC1 1.6054 3.4213 -1.5569 0.4503
SKN-3 GDSC1 1.7275 3.7013 -1.6106 0.5465
SAT [Human HNSCC] GDSC1 2.2412 4.732 -1.7845 0.8126
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RT-112 GDSC1 -2.4241 0.778 -3.2273 23.7282
SW780 GDSC1 -1.4472 1.0753 -2.4109 13.2488
RT-4 GDSC1 -1.4354 3.8559 -3.7784 22.6518
SW1710 GDSC1 -1.4345 1.0696 -2.3964 13.0842
J82 GDSC1 -1.0609 0.9068 -1.9825 8.3684
647V GDSC1 -0.99 0.9067 -1.9223 7.6305
HT-1197 GDSC1 -0.7452 1.3025 -1.9218 6.7758
5637 GDSC1 -0.4652 1.4819 -1.8017 4.9847
BFTC-905 GDSC1 -0.4375 1.3912 -1.7383 4.4242
639V GDSC1 -0.4164 2.3958 -2.2136 8.0012
HT-1376 GDSC1 -0.3284 2.7351 -2.3156 8.5124
KU-19-19 GDSC1 1.0876 2.9019 -1.5718 0.8246
UM-UC-3 GDSC1 1.0976 2.7638 -1.5159 0.604
CAL-29 GDSC1 1.2031 2.8467 -1.5046 0.5012
TCCSUP GDSC1 1.3516 9.8732 -4.5965 17.9745
T24 GDSC1 1.4 3.1628 -1.5426 0.5122
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Ca Ski GDSC1 -1.7199 -0.3762 -2.0007 11.3806
SKN GDSC1 -1.6452 0.6955 -2.4136 14.1291
CAL-39 GDSC1 -1.2627 1.1783 -2.2943 11.5919
DoTc2 4510 GDSC1 -1.125 0.6034 -1.8867 7.8609
ME-180 GDSC1 -1.0657 0.4374 -1.7523 6.5745
KGN GDSC1 -0.9426 1.8475 -2.3532 10.8293
BPH-1 GDSC1 -0.8869 1.1529 -1.9601 7.5588
SW954 GDSC1 -0.8848 0.5387 -1.6517 5.123
NCC-IT GDSC1 -0.8133 1.9273 -2.2873 9.8601
HEC-1 GDSC1 -0.5441 1.2946 -1.7667 4.9431
LB831-BLC GDSC1 -0.4853 2.1278 -2.1327 7.5907
NT2-D1 GDSC1 -0.4464 3.8321 -2.9468 13.5368
SW962 GDSC1 -0.2694 1.3968 -1.6294 3.1841
NEC8 GDSC1 -0.1912 3.3108 -2.4979 9.4699
HeLa GDSC1 0.032 2.8231 -2.1072 5.9515
OVMIU GDSC1 0.124 2.2513 -1.7824 3.3998
C-33 A GDSC1 0.1635 2.414 -1.8331 3.669
SiHa GDSC1 0.3694 2.0882 -1.5759 1.6303
SKG-IIIa GDSC1 0.4923 2.2632 -1.5879 1.528
OMC-1 [Human cervical carcinoma] GDSC1 0.5698 2.4653 -1.6336 1.6804
DSH1 GDSC1 0.829 10.161 -5.1135 21.7155
C-4-I GDSC1 1.2328 2.9483 -1.53 0.5673
SW756 GDSC1 1.2624 2.6373 -1.4083 0.2191
PA-1 GDSC1 1.4034 2.9816 -1.4768 0.3257
HT-3 GDSC1 1.4075 3.264 -1.5765 0.618
JEG-3 GDSC1 1.4695 3.1004 -1.4941 0.3424
SiSo GDSC1 1.5926 3.4737 -1.5805 0.5258
MS751 GDSC1 1.73 3.2525 -1.4531 0.1753
JAR GDSC1 1.8173 3.3654 -1.4609 0.168
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ponatinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Ponatinib and Acalabrutinib. Mature B-cell lymphoma [2A85] [9]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Ponatinib and Ibrutinib. Mature B-cell lymphoma [2A85] [9]
Coadministration of a Drug Treating the Disease Different from Ponatinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Ponatinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [10]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Ponatinib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [10]
Arn-509 DMT81LZ Moderate Increased metabolism of Ponatinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [10]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Ponatinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [11]
Troleandomycin DMUZNIG Major Decreased metabolism of Ponatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [10]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Ponatinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [12]
Talazoparib DM1KS78 Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [13]
Tucatinib DMBESUA Major Decreased metabolism of Ponatinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [10]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Ponatinib and Levomilnacipran. Chronic pain [MG30] [14]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Ponatinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [10]
MK-8228 DMOB58Q Moderate Decreased metabolism of Ponatinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [9]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Ponatinib and Vortioxetine. Depression [6A70-6A7Z] [14]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Ponatinib due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [10]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ponatinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [9]
Tazemetostat DMWP1BH Moderate Increased metabolism of Ponatinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [10]
Ripretinib DM958QB Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [10]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Ponatinib and Avapritinib. Gastrointestinal stromal tumour [2B5B] [9]
Cobicistat DM6L4H2 Major Decreased metabolism of Ponatinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [10]
Aliskiren DM1BV7W Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [15]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Ponatinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [9]
Naloxegol DML0B41 Minor Decreased clearance of Ponatinib due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [16]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Ponatinib caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [17]
Ceritinib DMB920Z Major Decreased metabolism of Ponatinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [10]
PF-06463922 DMKM7EW Moderate Increased metabolism of Ponatinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [10]
Selpercatinib DMZR15V Moderate Decreased metabolism of Ponatinib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [18]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Ponatinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [19]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Ponatinib and Idelalisib. Mature B-cell leukaemia [2A82] [20]
GDC-0199 DMH0QKA Major Decreased clearance of Ponatinib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [10]
IPI-145 DMWA24P Moderate Decreased metabolism of Ponatinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [21]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Ponatinib and Arry-162. Melanoma [2C30] [9]
LGX818 DMNQXV8 Major Increased risk of bleeding by the combination of Ponatinib and LGX818. Melanoma [2C30] [9]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Ponatinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [10]
Ubrogepant DM749I3 Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Ubrogepant. Migraine [8A80] [22]
Rimegepant DMHOAUG Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Rimegepant. Migraine [8A80] [23]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Ponatinib and Tecfidera. Multiple sclerosis [8A40] [24]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Ponatinib and Siponimod. Multiple sclerosis [8A40] [10]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Ponatinib and Ocrelizumab. Multiple sclerosis [8A40] [25]
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Ponatinib and Fedratinib. Myeloproliferative neoplasm [2A20] [9]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Ponatinib and Vorapaxar. Myocardial infarction [BA41-BA43] [9]
Netupitant DMEKAYI Moderate Decreased metabolism of Ponatinib caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [9]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Ponatinib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [26]
Abametapir DM2RX0I Moderate Decreased metabolism of Ponatinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [27]
Lefamulin DME6G97 Moderate Decreased metabolism of Ponatinib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [28]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Ponatinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [9]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Ponatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [17]
LEE011 DMMX75K Moderate Decreased metabolism of Ponatinib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [9]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [26]
Elagolix DMB2C0E Moderate Increased metabolism of Ponatinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [10]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Ponatinib and Betrixaban. Venous thromboembolism [BD72] [9]
⏷ Show the Full List of 49 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ponatinib Hydrochloride eq 10mg base tablet eq 10mg base Tablet Oral
Ponatinib Hydrochloride eq 15mg base tablet eq 15mg base Tablet Oral
Ponatinib Hydrochloride eq 30mg base tablet eq 30mg base Tablet Oral
Ponatinib Hydrochloride eq 45mg base tablet eq 45mg base Tablet Oral
Ponatinib 15 mg tablet 15 mg Oral Tablet Oral
Ponatinib 30 mg tablet 30 mg Oral Tablet Oral
Ponatinib 45 mg tablet 45 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5890).
2 Ponatinib FDA Label
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
6 Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Dev. 2015 Sep;4(5):354-60.
7 Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 2017 Oct;363(1):12-19.
8 Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther. 2013 Aug 20;6:1111-8.
9 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
10 Cerner Multum, Inc. "Australian Product Information.".
11 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
12 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
13 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
14 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
15 Canadian Pharmacists Association.
16 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
19 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
20 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
21 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
22 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
23 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
24 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
25 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
26 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
27 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
28 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.